FIELD: medicine.
SUBSTANCE: group of inventions relates to a method for increasing the level of ethyl eicosapentaenoic acid (EPA) in plasma and/or serum in a patient in need thereof, comprising administering to a patient, daily, a pharmaceutical composition comprising at least 96 wt % ethyl eicosapentaenoate, 0.2 to 0.5 wt % ethyl octadecatetraenoate, from 0.05 % to 0.25 % by weight of ethyl nonaecapentaenoate, from 0.2 % to 0.45 % by weight of ethyl arachidonate, from 0.3 % to 0.5 % by weight of ethyl eicosatetraenoate, from 0.05 % to 0.32 % of ethyl geneicosapentaenoate and not more than 0.05 % of ethyl docosahexaenoic acid (ethyl-DHA), if present, in an amount sufficient to raise EPA levels in a patient in plasma and/or serum by at least 200 % compared to the initial one, refers to a method for increasing plasma and/or serum EPA levels in a patient, in need thereof, comprising administering to a patient a pharmaceutical composition comprising at least 96 wt % ethyl eicosapentaenoate, 0.2 to 0.5 wt % ethyl octadecatetraenoate, 0.05 to 0.25 wt % ethyl nonaecapentaenoate, from 0.2 % to 0.45 % by weight of ethyl arachidonate, from 0.3 % to 0.5 % by weight of ethyl eicosatetraenoate, from 0.05 % to 0.32 % of ethyl geneicosapentaenoate and not more than 0.05 % of ethyl-DHA, where daily introduction of 2 g of the composition to a patient for at least 6 weeks, the patient exhibits at least 200 % increase in plasma and/or serum EPA levels as compared to the initial, and relates to a method of increasing the level of EPA in a patient's plasma or serum, comprising administering to a patient a pharmaceutical composition, including at least 96 % by weight of ethyl eicosapentaenoate, from 0.2 % to 0.5 % by weight of ethyl octadecatetraenoate, from 0.05 % to 0.25 % by weight of ethyl nonaecapentaenoate, from 0.2 % to 0.45 % by weight ethyl arachidonate, from 0.3 % to 0.5 % by weight of ethyl eicosatetraenoate, from 0.05 % to 0.32 % of ethyl geneicosapentaenoate and not more than 0.05 % of ethyl-DHA, where daily introduction of 4 g of composition to patient for at least approximately 6 weeks, patient exhibits at least approximately 300 % increase in the level of EPA in plasma and/or serum as compared to the initial one.
EFFECT: group of inventions provides improved methods of treating diseases and disorders associated with the cardiovascular system.
19 cl, 2 dwg, 8 tbl, 4 ex
